{"id":6297,"date":"2022-01-03T18:10:31","date_gmt":"2022-01-03T17:10:31","guid":{"rendered":"https:\/\/www.ab-science.com\/?p=6297"},"modified":"2022-01-06T17:22:02","modified_gmt":"2022-01-06T16:22:02","slug":"ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques","status":"publish","type":"post","link":"https:\/\/www.ab-science.com\/fr\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\/","title":{"rendered":"AB Science a re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude confirmatoire de Phase III avec le masitinib dans les formes progressives de la scl\u00e9rose en plaques"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text]<\/p>\n<h3 class=\"Default\">03\/01\/2022 \u2013 AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude de Phase III (AB20009) \u00e9valuant le masitinib chez les patients atteints de scl\u00e9rose en plaques progressive primaire (PPMS) ou de scl\u00e9rose en plaques secondairement progressive non-active (nSPMS)<\/h3>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<iframe width=\"100%\" height=\"800\" src=\"https:\/\/www.ab-science.com\/themencode-pdf-viewer-sc\/?tnc_pvfw=ZmlsZT1odHRwczovL3d3dy5hYi1zY2llbmNlLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyMi8wMS9DUC1QaGFzZS1JSUktTVMtQU5TTS1WRlItVkYucGRmJnNldHRpbmdzPTExMTAxMTExMTExMTExMTExMDAmbGFuZz1lbi1VUw==#page=&zoom=100&pagemode=none\" title=\"\"><\/iframe>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">#default-btn-308cd01a6fdca1367c3def479dcbb565.ico-right-side > i {\n  margin-right: 0px;\n  margin-left: 8px;\n}\n#default-btn-308cd01a6fdca1367c3def479dcbb565 > i {\n  margin-right: 8px;\n}<\/style><div class=\"btn-align-center\"><a href=\"https:\/\/www.ab-science.com\/wp-content\/uploads\/2022\/01\/CP-Phase-III-MS-ANSM-VFR-VF.pdf\" class=\"default-btn-shortcode dt-btn dt-btn-l link-hover-off  vc_custom_1641230000117\" target=\"_blank\" id=\"default-btn-308cd01a6fdca1367c3def479dcbb565\" rel=\"noopener\"><i class=\"dt-icon-the7-download\"><\/i><span>T\u00e9l\u00e9charger le PDF<\/span><\/a><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text] 03\/01\/2022 \u2013 AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude de Phase III (AB20009) \u00e9valuant le masitinib chez les patients atteints de scl\u00e9rose en plaques progressive primaire (PPMS) ou de scl\u00e9rose en plaques secondairement progressive non-active (nSPMS) [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[117,121,93,116],"class_list":["post-6297","post","type-post","status-publish","format-standard","hentry","category-2022-fr","tag-ab10015","tag-als-fr","tag-masitinib-fr","tag-riluzole","category-127","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Autorisation re\u00e7ue pour initier une \u00e9tude confirmatoire de Phase III<\/title>\n<meta name=\"description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude de Phase III (AB20009)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB Science a re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude confirmatoire de Phase III avec le masitinib dans les formes progressives de la scl\u00e9rose en plaques\" \/>\n<meta property=\"og:description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude de Phase III (AB20009)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-03T17:10:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-06T16:22:02+00:00\" \/>\n<meta name=\"author\" content=\"Alexis BERNARD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis BERNARD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\\\/\"},\"author\":{\"name\":\"Alexis BERNARD\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\"},\"headline\":\"AB Science a re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude confirmatoire de Phase III avec le masitinib dans les formes progressives de la scl\u00e9rose en plaques\",\"datePublished\":\"2022-01-03T17:10:31+00:00\",\"dateModified\":\"2022-01-06T16:22:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\\\/\"},\"wordCount\":174,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"keywords\":[\"AB10015\",\"ALS\",\"Masitinib\",\"riluzole\"],\"articleSection\":[\"2022\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\\\/\",\"name\":\"Autorisation re\u00e7ue pour initier une \u00e9tude confirmatoire de Phase III\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2022-01-03T17:10:31+00:00\",\"dateModified\":\"2022-01-06T16:22:02+00:00\",\"description\":\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude de Phase III (AB20009)\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AB Science a re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude confirmatoire de Phase III avec le masitinib dans les formes progressives de la scl\u00e9rose en plaques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\",\"name\":\"Alexis BERNARD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"caption\":\"Alexis BERNARD\"},\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/author\\\/abernard\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Autorisation re\u00e7ue pour initier une \u00e9tude confirmatoire de Phase III","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude de Phase III (AB20009)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\/","og_locale":"fr_FR","og_type":"article","og_title":"AB Science a re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude confirmatoire de Phase III avec le masitinib dans les formes progressives de la scl\u00e9rose en plaques","og_description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude de Phase III (AB20009)","og_url":"https:\/\/www.ab-science.com\/fr\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\/","og_site_name":"AB Science","article_published_time":"2022-01-03T17:10:31+00:00","article_modified_time":"2022-01-06T16:22:02+00:00","author":"Alexis BERNARD","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Alexis BERNARD","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\/#article","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\/"},"author":{"name":"Alexis BERNARD","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755"},"headline":"AB Science a re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude confirmatoire de Phase III avec le masitinib dans les formes progressives de la scl\u00e9rose en plaques","datePublished":"2022-01-03T17:10:31+00:00","dateModified":"2022-01-06T16:22:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\/"},"wordCount":174,"publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"keywords":["AB10015","ALS","Masitinib","riluzole"],"articleSection":["2022"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\/","url":"https:\/\/www.ab-science.com\/fr\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\/","name":"Autorisation re\u00e7ue pour initier une \u00e9tude confirmatoire de Phase III","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2022-01-03T17:10:31+00:00","dateModified":"2022-01-06T16:22:02+00:00","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude de Phase III (AB20009)","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-a-recu-lautorisation-de-lansm-pour-initier-une-etude-confirmatoire-de-phase-iii-avec-le-masitinib-dans-les-formes-progressives-de-la-sclerose-en-plaques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"AB Science a re\u00e7u l\u2019autorisation de l\u2019ANSM pour initier une \u00e9tude confirmatoire de Phase III avec le masitinib dans les formes progressives de la scl\u00e9rose en plaques"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]},{"@type":"Person","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755","name":"Alexis BERNARD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","caption":"Alexis BERNARD"},"url":"https:\/\/www.ab-science.com\/fr\/author\/abernard\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/6297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=6297"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/6297\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=6297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/categories?post=6297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/tags?post=6297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}